Lupus & antiphospholipid syndrome
Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study
Main finding · Renal objective remission rateResult — go to the resultDifference 5.7 percentage points 95% CI −25.8 to 26.8Authors' conclusion
The sequential treatment of belimumab or telitacicept following RTX may represent a promising therapeutic approach in the management of refractory lupus nephritis.
Study context
- Population
- Patients with refractory LN from four independent centres
- Participants
- 49 patients4 centres
- Exposure
- Rituximab (RTX) followed by belimumab vs RTX followed by telitacicept
- Belimumabn = 35
- Telitaciceptn = 14
- Outcome
- Renal response rates
Methodological detailsreal-world, multicentre
- Real-world
- Multicentre
Main finding
Renal objective remission rate · follow-up 26±12 months
Difference
5.7 percentage points
95% CI −25.8 to 26.8
P = 1.000
Events by group
Telitaciceptvs Belimumab
difference 5.7 percentage points (95% CI −25.8 to 26.8); P = 1.000
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Belimumab | Telitacicept | Difference (percentage points) (95% CI) | P value | |
|---|---|---|---|---|---|
| Renal complete response · follow-up 26±12 months | 54.3% | 78.6% | 24.3 (9.7–47.8) | P = 0.194 | |
| −200204060Difference, percentage points (linear scale) |
Anti-dsDNA, complement, estimated glomerular filtration rate (eGFR), urinary protein creatinine ratio (uPCR), SLEDAI-2K and prednisone dose
- Anti-dsDNA, complement, eGFR, uPCR and SLEDAI-2K improved in both groups, with a significant reduction in prednisone dose
Death
- No death occurred
Safety
Major adverse effects
- Immunoglobulin deficiency, respiratory tract infection and urinary tract infection
Original publication
Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study. Lupus Sci Med. Published 6 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →